Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Prostaglandins are found in most tissues and organs. They are produced by almost all nucleated cells. They are autocrine and paracrine lipid mediators that act upon platelets, endothelium, uterine and mast cells. They are synthesized in the cell from the fatty acid arachidonic acid. Arachidonic acid is created from diacylglycerol via phospholipase-A2, then brought to either the cyclooxygenase pathway or the lipoxygenase pathway. The cyclooxygenase pathway produces thromboxane, prostacyclin and prostaglandin D, E and F. Alternatively, the lipoxygenase enzyme pathway is active in leukocytes and in macrophages and synthesizes leukotrienes.
Noma (also known as gangrenous stomatitis or cancrum oris) is a rapidly-progressive and often-fatal gangrenous infection of the mouth and face. Noma usually begins as an ulcer on the gums and rapidly spreads into the jawbone, cheek, and facial soft tissues. This is followed by death of the facial tissues and fatal sepsis. Survivors are left with severe facial disfigurement often with impairments in breathing, swallowing, speaking, and vision. In 2023, Noma was added to the World Health Organization's list of neglected tropical diseases. This disease is linked to poverty and malnutrition; noma has also been seen in severely immunocompromised people in the developed world. It is preventable by proper nutrition and oral hygiene. Noma is most common in impoverished environments with poor healthcare infrastructure; as a result, many cases go undiagnosed, untreated, and unreported. It is an opportunistic infection linked to several microbes that take advantage of malnutrition and compromised immunity. There is no evidence of direct transmission from person to person. In the early stages, it can be treated effectively with antibiotics and nutrition supplements. If diagnosed early enough, there can be proper wound healing. After recovering, patients with disfigurement require complex surgical rehabilitation. There are no reliable estimates of its prevalence – in 1998 WHO estimated that there were 140,000 cases per year with a fatality rate of 90%.
The three substrates of this enzyme are formaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are formic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is formaldehyde:NAD+ oxidoreductase. Other names in common use include NAD+-linked formaldehyde dehydrogenase, s-nitrosoglutathione reductase (GSNO reductase) and NAD+-dependent formaldehyde dehydrogenase. This enzyme participates in methane metabolism.
Sources: en.wikipedia.org
Delcy Rodríguez endorsed the agreement, saying it would have a "significant impact on our nation's revival" and generate more than $200 billion in tax revenue for the government. The newspaper reported that Chevron was separately in advanced talks to expand its own production in the country. It also reported that any meaningful new production would take years to materialise, so the agreement would have little immediate effect on global commodity prices or on what United States consumers pay for fuel; Venezuela was producing a little over one million barrels a day, about one per cent of global output and roughly the same share as under Maduro. The announcement followed earlier reports that the Trump administration had been in advanced negotiations to acquire a direct stake in Venezuelan oilfields. These reports had already generated unease among members of Venezuela's opposition. One opposition figure, speaking anonymously due to the sensitivities of criticizing the United States, described the proposed arrangement as "a land grab – a massive land grab," adding that it was "revolting" and represented "a rapacious, mafioso United States," in contrast to the United States of the Marshall Plan. Ricardo Hausmann, a former Venezuelan minister in exile and opposition supporter, wrote on X that an illegitimate interim government lacked the legitimacy to sign what he termed an unconstitutional agreement, and predicted that it would fail for all parties involved.
=== Pivot to scientific instruments === HVEC had originally built products for clients in cancer therapy and industrial radiography, but its machines proved valuable for basic research. The company's proximity to MIT research gave it unique advantages in understanding accelerator requirements. Van de Graaff, Trump, and fellow board member William Buechner regularly consulted with physicists pushing the boundaries of nuclear structure studies, translating experimental needs into engineering specifications. In 1949, Brookhaven National Laboratory commissioned HVEC to build a 4 MeV Van de Graaff particle injector for its planned high-energy Cosmotron accelerator. When completed in 1953, the Cosmotron became the first accelerator to exceed billion-electronvolt potentials. HVEC's standard 2 MV accelerators also found nuclear science customers, including the Naval Research Laboratory and European universities. In 1951, HVEC adopted a Trump-designed MIT accelerator as a research accelerator prototype. This single-stage "CN" model was the first mass-produced research accelerator. CN machines operated at voltages up to 6.5 megavolts and established HVEC's reputation for reliability in nuclear research applications. In 1954, Canada's Chalk River Laboratories asked HVEC to modify the CN into higher-voltage tandem accelerator, yielding a highly profitable product line that sustained the company for fifteen years.
== Contraindications == Like other non-selective beta blockers, levobunolol is contraindicated in patients with airway diseases such as asthma and severe chronic obstructive pulmonary disease (COPD), as well as heart problems such as sinus bradycardia, second- or third-degree atrioventricular block, sick sinus syndrome, and cardiogenic shock. Combination with MAO-A inhibitors is also contraindicated because it could cause a dangerous rise in blood pressure. Levobunolol is not useful for the treatment of closed-angle glaucoma.
Sources: en.wikipedia.org
The first season of Beast Games, a reality competition show created by Jimmy "MrBeast" Donaldson was first released on Amazon Prime Video on December 19, 2024 and concluded on February 13, 2025. Jeffrey Randall Allen won the season, defeating Twana Barnett. Allen won a total grand prize of $10,000,000.
The United States occupied Iraq between the toppling of the Ba'athist Iraqi government and the dissolution of the Coalition Provisional Authority on 28 June 2004. Thereafter, the United States remained in Iraq after obtaining United Nations Security Council approvals and resolutions, negotiated with involvement from the Transitional Government of Iraq. On 1 January 2009, the Government of Iraq obtained full responsibility for security in all of Iraq. Consequently, United States Forces – Iraq did not have responsibility for, nor control of, any ground in Iraq. Its mission was limited to defense and security cooperation only.
In 1966, E. O. Wilson and his colleagues identified the fossil remains of an ant (Sphecomyrma) that lived in the Cretaceous period. The specimen, trapped in amber dating back to around 92 million years ago, has features found in some wasps, but not found in modern ants. The oldest fossils of ants date to the mid-Cretaceous, around 113–100 million years ago, which belong to extinct stem-groups such as the Haidomyrmecinae, Sphecomyrminae and Zigrasimeciinae, with modern ant subfamilies appearing towards the end of the Cretaceous around 80–70 million years ago. Ants diversified extensively during the Angiosperm Terrestrial Revolution and assumed ecological dominance around 60 million years ago. Some groups, such as the Leptanillinae and Martialinae, are suggested to have diversified from early primitive ants that were likely to have been predators underneath the surface of the soil. During the Cretaceous period, a few species of primitive ants ranged widely on the Laurasian supercontinent (the Northern Hemisphere). Their representation in the fossil record is poor, in comparison to the populations of other insects, representing only about 1% of fossil evidence of insects in the era. Ants became dominant after adaptive radiation at the beginning of the Paleogene period. By the Oligocene and Miocene, ants had come to represent 20–40% of all insects found in major fossil deposits. Of the species that lived in the Eocene epoch, around one in 10 genera survive to the present.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.